All Playbooks

PLAYBOOK · NUTRA · UK / EU

Card Acquiring for UK / EU Nutraceutical Brands
Novel Foods & EFSA Compliance

Selling supplements into the UK and EU means card acquirers will read your ingredient deck against the EU Novel Foods Regulation (2015/2283) and the FSA's Great Britain novel foods list. Ingredients without a positive EFSA opinion or an FSA authorisation route are the single biggest reason underwriting stalls — even when chargebacks and refund ratios look clean.

Check Your Approval OddsFree · No sign-up

WHY THIS COMBINATION IS HARD

What goes wrong when generalist acquirers see this profile.

Novel Foods ingredient screening

Acquirer underwriting now reads SKUs against the EU Union list of novel foods and the FSA's CBD public list. An ingredient like NMN, 6-paradol, or a concentrated botanical isolate without a validated EFSA application or FSA authorisation route is a hard decline — regardless of the merchant's processing history.

VAMP exposure on subscription/auto-ship models

Most nutra economics depend on auto-replenishment, which historically attracts dispute reason codes 13.2 (cancelled recurring) and 10.4 (other fraud). Under the consolidated Visa Acquirer Monitoring Program, count-based ratios make supplements one of the categories acquirers actively portfolio-manage to stay under threshold.

Health claim and pre-checkout copy review

EU Regulation 1924/2006 on nutrition and health claims, plus the UK's parallel regime, mean acquirers screen landing pages for unapproved disease claims, before/after imagery and 'clinically proven' language. A non-compliant claim on a sales funnel can trigger MATCH listing or termination, even if the product itself is legal.

MCC misclassification risk

Generalist acquirers often try to board nutra under 5499 (Misc Food Stores) or 5814 (Fast Food) to keep fees low. Scheme reclassification to 5912 (Drug Stores), 5122 (Drugs, Druggists' Sundries) or 7298 (Health & Beauty) mid-cycle exposes the merchant to retroactive interchange and a higher dispute multiplier.

Cross-border IBAN and PSD2 friction

Brands routing UK settlement through an EU PSP (or vice-versa post-Brexit) increasingly hit IBAN discrimination complaints and SCA exemption mismatches on recurring transactions, both of which surface as fraud disputes rather than authentication failures.

Free-trial and negative-option historical baggage

Card schemes still treat free-trial-to-subscription nutra as one of the highest-watch flows after the FTC and CMA actions of the 2020s. New applicants inherit category-level scepticism even with a clean continuity model and clear cancellation paths.

WHAT TO EXPECT

Realistic terms for this combination.

ROLLING RESERVE

5-10% rolling over 180 days for compliant SKUs; 10-15% over 180 days for CBD, mushroom extracts or borderline novel-food ingredients

SETTLEMENT

T+3 to T+7, with T+14 not unusual on first 90 days

MCC CODES

5499, 5912, 5122, 8099, 7298

Scheme reporting: VAMP count-based ratio replacing VDMP/VFMP means subscription cancellation disputes count toward the same bucket as fraud. Misclassification between 5499 and 5912 is a frequent trigger for scheme reviews on nutra portfolios.

ACQUIRER LANDSCAPE

Who actually underwrites this combination.

The active pool for UK/EU nutra is dominated by EU credit institutions with documented health-and-wellness programmes, UK-licensed acquirers with high-risk desks that maintain a positive list of permitted ingredients, and a smaller set of specialist PSPs that have built Novel Foods screening into their onboarding. This pool differs from generalist acquirers in that they pre-clear SKUs against the Union list and FSA register, accept rolling reserves as a structural feature rather than a remediation step, and price chargeback ratios up to roughly 1% rather than declining at 0.65%.

HOW ICETREE APPROACHES IT

Our approach for merchants in this combination.

  • We pre-screen your full SKU list against the EU Union list of novel foods and the FSA Great Britain register before any acquirer introduction, so non-compliant ingredients are flagged before underwriting sees them.
  • We match you to acquirers with documented nutra programmes that price for subscription models rather than penalising them under VAMP.
  • We negotiate reserve percentage and release schedule based on your actual chargeback ledger and refund policy, not the category default.
  • We review your sales funnel and product page copy for Regulation 1924/2006 health-claim risk before submission, reducing back-and-forth on application.
  • We structure multi-acquirer setups across UK and EU entities so you're not single-points-of-failure on one MID.

FAQ

Common questions answered.

Most specialist acquirers will board the merchant but exclude the pending-review SKU from the permitted product list until EFSA publishes a positive opinion and the Commission updates the Union list. We negotiate this exclusion explicitly so the rest of your range can process while the application proceeds.

If your CBD product is on the FSA's public list of products linked to a validated novel food application, UK acquirers with CBD programmes will consider it. Products not on the list, or removed from it, are effectively unboardable under any UK-licensed acquirer's risk policy.

Compliant supplement SKUs with a clean continuity flow typically see 5-10% rolling reserves over 180 days. CBD, nootropics with novel-food exposure, or aggressive free-trial models push to 10-15% over 180 days, sometimes with a step-down schedule tied to dispute ratio performance.

5912 (Drug Stores) generally carries higher interchange and is more closely monitored under VAMP than 5499 (Misc Food Stores). We push for 5499 where the product mix legitimately supports it and ensure the acquirer's classification matches scheme guidance so you're not exposed to mid-cycle reclassification.

Practically yes. Post-Brexit, SCA exemptions, settlement currency and IBAN discrimination rules are cleaner with a UK acquirer for GBP volume and an EU-licensed acquirer for EUR. We structure both legs so your continuity programme isn't disrupted by single-acquirer policy changes.

Three things in order: unapproved disease claims on the landing page, an ingredient that appears on EFSA's negative list or the FSA's removed-product register, and a dispute ratio above the VAMP threshold for two consecutive months. The first two are pre-checkout fixes; the third is operational.

Want IceTree on your side?

Run the Approval Predictor for a 2-minute estimate of your acquirer fit, expected reserve range, and what to prepare — specific to United Kingdom / EU and Novel Foods / EFSA.

We use cookies to analyse site performance and measure the effectiveness of our outreach. Privacy policy